Bile acids are polar derivatives of cholesterol essential for the absorption of dietary lipids and regulate the transcription of genes that control cholesterol homeostasis. Recently it have been identified the synthetic chenodeoxycholic acid (CDCA) derivatives HS-1200 and cisplatin showed apoptisis-inducing activity on various cancer cells in vivo and in vitro. This study was undertaken to investigate the synergistic apoptotic effect of co-treatment with HS-1200 and cisplatin on human tongue squamous cell carcinoma cells (SCC25 cells).
Ⅰ. INTRODUCTION Cells undergoing apoptosis usually develop characteristic changes, including nuclear condensation and degradation of DNA into oligonucleosomal fragments. 1) Apoptotic cell death is thought to result ultimately from the proteolytic actions of caspase 2) and alterations in mitochondrial function play a key role in the regulation of apoptosis. 3) Moreover, the proteasome system has been shown to be implicated as a negative or positive mediator of apoptosis. The proteasome pathway is known to work mostly in upstream of mitochondrial alterations and caspase activation. 4) Carcinoma of the oral cavity, especially oral squamous cell carcinoma (OSCC), are one of the most leading causes of cancer related death and affect nearly 500,000 patients annually world-wide. And OSCC is one of the most malignancies that remain incurable with current therapies. 5) OSCC patients are treated by classical modalities of treatment consisting of surgery, radiotherapy, and/or chemotherapy. But OSCC still shows noticeable mortality rates. therefore new therapeutic approaches have been investigated and the most promising one is obtained from natural agents with known anti-cancer effects.
Bile acids are polar derivatives of cholesterol essential for the absorption of dietary lipids and regulate the transcription of genes that control cholesterol homeostasis. Different bile acids exhibit distinct biological effects. Importantly, natural bile salts were reported to inhibit cell proliferation and induce apoptosis in various cells. 6, 7) Several ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) derivatives developed by Im et al, 8, 9) and it have been reported that they had apoptosis-inducing effect in various cancer cells [10] [11] [12] [13] [14] .
Cisplatin is one of the most potent anticancer agents showing significant clinical activity against a variety of solid tumors belonging to a class of platinum containing anti-cancer compounds. 15) It is a representative of anticancer drug used to treat certain types of head and neck cancer, cervical carcinoma, lung cancer, neurologic cancers, and a wide variety of other cancers. However, its resistance remains a significant barrier to the survival of cancer patient.
Recent studies have demonstrated that the co-treatment of an antitumor agent having the synergistic anti-cancer effect can be one of the potential therapeutic strategies reducing the extent and severity of cancer treatment-related toxicity. To date, combination treatment of HS-1200 and cisplatin has systemic account of synergistic apoptotic effects on human squamous carcinoma cell line is still scarce. Here we have investigated the synergistic apoptotic effect of co-treatment with a chenodeoxycholic acid (CDCA) derivative, HS-1200 and an anticancer drug, cisplatin on human oral squamous carcinoma (SCC25) cell line.
Ⅱ. MATERIALS AND METHODS
Reagents
The synthetic bile acid derivative, HS-1200 was kindly provided by Professor Young-Hyun Yoo (Department of Anatomy, College of Medicine, Dong-A University, Busan, Korea). The following reagents were obtained commercially: Mouse monoclonal anti-human caspase-3, caspase-7, caspase-9, poly(ADP-ribose) polymerase (PARP), cytochrome c, apoptosis-inducing factor (AIF) antibodies, and rabbit polyclonal anti-human DFF40 (CAD), DFF45 (ICAD), β-actin antibodies, and FITC-conjugated goat anti-mouse and anti-rabbit IgGs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); HRP-conjugated sheep anti-mouse and anti-rabbit IgGs were from Amersham GE Healthcare (Little Chalfront, UK). 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol carbocyanine iodide (JC-1) was from Molecular Probes (Eugene, OR, USA). ApoScreenTM Annexin V-FITC Apoptosis Kit was from Beckman coulter (Fullerton, CA, USA). Suc-LLVY-AMC was from Calbiochem (Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM) and FBS were from Gibco (Gaithersburg, MD, USA). Dimethyl sulfoxide (DMSO), eugenol, cisplatin, Hoechst 33342, RNase A, proteinase K, aprotinin, leupeptin, PMSF, thiazolyl blue tetrazolium bromide and propidium iodide (PI) were from Sigma (St. Louis, MO, USA); SuperSignal West Pico enhanced chemiluminescence Western blotting detection reagent was from Pierce (Rockford, IL, USA).
Cell culture
The SCC25 human oral squamous carcinoma cell line was purchased from ATCC (Rockville, USA). Cells were maintained at 37℃ with 5% CO2 in air atmosphere in DMEM/F12 with 4 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose and 1.0 mM sodium pyruvate supplemented with 10% FBS. 3 . Treatment of HS-1200 and cisplatin for co-treatment
Stock solutions of HS-1200 (100 mM) and cisplatin (25 mg/ml) made by dissolving them in DMSO were kept frozen at -20℃ until use. Twenty four hours after SCC25 cells were subcultured, the original medium was removed. The cells were washed with PBS and then incubated in the same fresh medium. Since single treatment of 25 μM HS-1200 and 4 μg/ml cisplatin for 24 h showed slight induction of cell death in MTT assay, this single concentration was utilized for further assessment of apoptosis for co-treatment. The concentration of DMSO used in this study had no effect on SCC25 cell proliferation in my preliminary studies. 4 . MTT assay SCC25 Cells were placed in a 96-well plate and were incubated for 24 h. Then they were treated with 25 μM HS-1200 and 4 μg/ml cisplatin for 24 h each and co-treatment with HS-1200/cisplatin were performed in the same condition for 24 h. After cells were treated with 500 μg/ml of thiazolyl blue tetrazolium bromide (MTT solution), they were incubated at 37℃ with 5% CO2 for 4 h. And then the medium was aspirated and formed formazan crystals were dissolved in DMSO. Cell viability was measured by an ELISA reader (Tecan, Männedorf, Switzerland) at 570 nm excitatory emission wavelength.
Hoechst staining
Cells were harvested and cell suspension was centrifuged onto a clean, fat-free glass slide with a cytocentrifuge. The samples were stained in 4 μg/ml Hoechst 33342 for 30 min at 37℃ and fixed for 10 min with 4% paraformaldehyde. 6 . DNA electrophoresis 2 x 10 6 cells were resuspended in 1.5 ml of lysis buffer [10 mM Tris (pH 7.5), 10 mM EDTA (pH 8. 0), 10 mM NaCl and 0.5% SDS] into which proteinase K (200 μg/ml) was added. After samples were incubated overnight at 48℃, 200 μl of ice cold 5 M NaCl was added and the supernatant containing fragmented DNA was collected after centrifugation. The DNA was then precipitated overnight at -20℃ in 50% isopropanol and Rnase A-treated for 1 h at 37℃. The DNA from 10 6 cells (15 μl) was equally loaded on each lane of 2% agarose gels in Tris-acetic acid/EDTA buffer containing 0.5 μg/ml ethidium bromide at 50 mA for 1.5 h. 
Western blot analysis
Cells (2 x 10 6 ) were washed twice in ice-cold PBS, resuspended in 200 μl ice-cold solubilizing buffer [300 mM NaCl, 50 mM Tris-Cl (pH 7.6), 0.5% Triton X-100, 2 mM PMSF, 2 μg/ml aprotinin and 2 μg/ml leupeptin] and incubated at 4℃ for 30 min. The lysates were centrifuged at 14,000 revolutions per min for 15 min at 4℃. Protein concentrations of cell lysates were determined with Bradford protein assay (Bio-Rad, Richmond, CA, USA) and 50 μg of proteins were loaded onto 7.5-15% SDS/PAGE. The gels were transferred to Nitrocellulose membrane (Amersham GE Healthcare, Little Chalfont, UK) and reacted with each antibody. Immunostaining with antibodies was performed using SuperSignal West Pico enhanced chemiluminescence substrate and detected with Alpha Imager HP (Alpha Innotech, Santa Clara, USA). 9 . Immunofluorescent staining Cells were cytocentrifuged and fixed for 10 min in 4% paraformaldehyde, incubated with each primary antibody for 1 h, washed 3 times for 5 min, and then incubated with FITC-conjugated secondary antibody for 1 h at room temperature. Cells were mounted with PBS. Fluorescent images were observed and analyzed under Zeiss LSM 700 laser-scanning confocal microscope (Göettingen, Germany). 10 . Assay of mitochondrial membrane potential (MMP)
JC-1 was added directly to the cell culture medium (1 μM final concentration) and incubated for 15 min. The medium was then replaced with PBS. Flow cytometry to measure MMP was performed on a CYTOMICS FC500 flow cytometry (Beckman Coulter, Brea, CA, USA). Data were acquired and analyzed using CXP software version 2.2.
11. Quantification of DNA hypoploidy by flow cytometry
After treatment for 24 h, cells were harvested by trypsinization and ice cold 95% ethanol with 0.5% Tween 20 was added to the cell suspensions to a final concentration of 70% ethanol. Fixed cells were pelleted, and washed in 1% BSA-PBS solution. Cells were resuspended in 1 ml PBS containing 20 μg/ml RNase A, incubated at 4℃ for 30 min, washed once with BSA-PBS, and resuspended in PI solution (10 μg/ml). After cells were incubated at 4℃ for 5 min in the dark, DNA content were measured on a CYTOMICS FC500 flow cytometry system (Beckman Coulter, FL, CA, USA) and data was analyzed using the Multicycle software which allowed a simultaneous estimation of cell-cycle parameters and apoptosis.
Ⅲ. RESULTS
1. Co-treatment with HS-1200 and cisplatin augmented the reduction in viability of SCC25 cells.
To investigate whether the co-treatment with HS-1200 and cisplatin reduced the viability of SCC25 cells, MTT assay was conducted. Single treatment of HS-1200 at 25 μM or cisplatin at 4 μ g/ml for 24 h reduced the viability of SCC25 cells slightly (HS-1200, 94.6%; cisplatin, 93.4%). Co-treatment with HS-1200 and cisplatin significantly reduced the to 45.2% cell viability vs single treatment (Fig. 1). 2. Co-treatment with HS-1200 and cisplatin augmented the nuclear condensation in SCC25 cells.
To study a nuclear condensation induced by the co-treatment, Hoechst staining by which a hallmark of apoptosis was conducted. Hoechst staining showed a nuclear condensation by the single treatment of HS-1200 and cisplatin. Co-treatment 1200 and cisplatin remarkably reduced the proteasome activity, compared to the example of the single treatment (Fig. 4) . 5 . Augmentation of apoptosis by the cotreatment with HS-1200 and cisplatin was demonstrated by reduction of mitochondrial membrane potential (MMP) in SCC25 cells.
Single treatment with either HS-1200 or cisplatin reduced slightly the MMP compared to control group. The co-treatment with HS-1200 and cisplatin result in the remarkable loss of MMP (Fig. 5) . 6 . Augmentation of apoptosis by the cotreatment with HS-1200 and cisplatin was demonstrated by the decrease in a DNA content of SCC25 cells.
The flow cytometry result showed that the cotreatment with HS-1200 and cisplatin significantly increased apoptotic cells with DNA hypoploidy compared to the example of single treatment (Fig. 6) . The confocal microscopy showed that AIF was located at mitochondria in the single treatment of HS-1200 or cisplatin whereas AIF was evidently translocated onto nuclei in the co-treatment (Fig. 7) . 8 . Co-treatment with HS-1200 and cisplatin caused the release of cytochrome c from mitochondria into the cytosol.
The confocal microscopy showed that cytochrome c was located at mitochondria in the single treatment with either HS-1200 or cisplatin whereas cytochrome c was evidently released into the cytosol by the co-treatment (Fig. 8) . The expression level of anti-apoptotic protein, Bcl-2 decreased and the expression level of apoptotic protein, Bax increased by the co-treatment (Fig. 9) . The co-treatment with HS-1200 and cisplatin induced the degradation of caspase-9, caspase-3, caspase-7 and PARP, and produced the processed DFF45 (ICAD) 11 kDa, PARP 85 kDa and caspase-3 17 kDA cleaved products (Fig. 10A and  Fig. 11) . The confocal microscopy showed that DFF40 (CAD) was located at cytosol by the single treatment with either HS-1200 or cisplatin whereas DFF40 (CAD) was evidently translocated into the nuclei by the co-treatment (Fig. 10B) .
Ⅳ. DISCUSSION Bile acids are steroid acids that is produced in mammalians liver and stored in the gall bladder. The function of bile acid is to facilitate the formation of micelles, which promotes processing of dietary fat. Several reports demonstrated that natural bile salts, ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) were inhibit cell proliferation and induce apoptosis in various cells. [10] [11] [12] [13] [14] Also, it has been reported that the synthetic CDCA derivatives induce the antiproliferative efficacy in various cancer cells by inducing apoptosis. Those studies demonstrated the decrease of proteasome activity, mitochondrial events, and nuclear condensation [16] [17] [18] in synthetic CDCA derivatives-induced apoptosis. In addition, it has been demonstrated that a synthetic CDCA derivative, HS-1200 shows the strongest apoptosis-inducing effect among the synthetic CDCA derivatives. 11, 14, 18) Since from the 1970s, the neutral, square planar, coordination complex cis-diamminedichloroplatinum (II) (cisplatin) has become more and more popular in the treatment of cancer. Cisplatin, which is a well-known DNA-damaging agent and one of the most active cancer treatment agents available, is widely used for the treatment of many malignancies, including testicular, ovarian, bladder, cervical, head and neck, and small-cell and non-small-cell lung cancers. Unfortunately, however, cisplatin causes many untoward side effects. 19, 20) It have been reported that cisplatin-induced cell death is involved in apoptotic-and cell cycle-regulating pathways. [21] [22] [23] [24] [25] [26] [27] Moreover, the synergistic antitumor effect of the combination treatment with cisplatin and antitumor agents or natural products have also been demonstrated. [28] [29] [30] [31] If the co-treatment with a synthetic CDCA derivative, HS-1200 and a representative of anticancer drug, cisplatin which has severe toxicity and resistance in the chemotherapy, shows a synergistic antitumor effect, it could be a more fundamental therapeutic strategy for cancer chemotherapy.
Proteasome is a fundamental non-lysosomal tool that cells use to process or degrade a variety of short-living proteins. It was reported that proteolysis mediated by ubiquitin-proteasome system has been reported to be implicated in the regulation of apoptosis. 32) The proteasome pathway is mostly known to work at the upstream of the mitochondrial alterations and caspase activation. 4) In this study, the co-treatment with HS-1200 and cisplatin on SCC25 cells causes the significant reduction of proteasome acitivity compared to the single treatment.
Mitochondria plays an important role in the induction of the mitochondrial permeability transition and also plays a key part in the regulation of apoptosis. 3, 33, 34) Outer mitochondrial membrane becomes permeable to intermembrane space proteins such as cytochrome c and AIF (apoptosis inducing factor) during apoptosis. 35) Release of cytochrome c and disruption of mitochondrial membrane potential (MMP) are known as features in apoptosis triggered by proteasome inhibition. 36, 37) On induction of apoptosis, AIF translocates to the nucleus, resulting in chromatin condensation and large-scale DNA fragmentation. 38) This study evidently showed that co-treatment with HS-1200 and cisplatin on SCC25 cells results in remarkable decrease of MMP, increase and decrease of Bax and Bcl-2, the release of cytochrome c into cytosol and translocation of AIF onto nuclei whereas the single treatment does not show these patterns.
A common final event of apoptosis is the nuclear condensation, which is controlled by caspases, DFF, and PARP. Caspases play an essential role during apoptotic death. 39) Once activated, the effector caspases (caspase-3, caspase-6 or caspase-7) are responsible for the proteolytic cleavage of a broad spectrum of cellular targets, ultimately leading to cell death. The known cellular substrates include structural components (such as actin and nuclear lamin), inhibitors of deoxyribonuclease (such as DFF45 or ICAD) and DNA repair proteins. (such as PARP) 40, 41) In apoptotic cells, activation of DFF40 (CAD), also a substrate of caspase-3, occurs with the cleavage of DFF45 (ICAD). Once DFF40 is activated and released from the complex of DFF45 and DFF40, it can translocate to the nucleus and then degrade chromosomal DNA and produce DNA fragmentation. 42) This study demonstrated that co-treatment with HS-1200 and cisplatin in SCC25 cells results in the degradation and the cleavage of caspase-9, caspase-3, caspase-7, PARP and DFF45 (ICAD), and also the translocation of DFF40 (CAD) onto nuclei whereas the single treatment does not.
Taken collectively, combination therapy with HS-1200 and cisplatin could be considered, in the future, as an alternative therapeutic strategy for human oral squamous carcinoma. Its clinical application awaits further extensive studies.
